

Company Heartbeats

Swiss companies - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
15 Oct 25	VAT Group	Q3 result	CHF 352.00	Call	BGUS3U	20 Mar 26	5.74	380.00	0.27	Calls on VAT Group
16 Oct 25	ABB	Q3 result	CHF 58.36	Call	SB1BRU	20 Mar 26	8.59	62.00	0.53	Calls on ABB
				Put	SL2B3U	20 Mar 26	7.50	50.00	0.28	Puts on ABB
20 Oct 25	Schindler	Q3 result	CHF 294.80	Call	BDAS4U	20 Mar 26	11.37	320.00	0.14	Calls on Schindler
23 Oct 25	Kuhne&Nagel	Q3 result	CHF 148.80	Call	S53BDU	20 Mar 26	8.29	160.00	0.14	Calls on Kuhne&Nagel
24 Oct 25	Galderma	Q3 result	CHF 142.10	Call	S36BIU	20 Mar 26	6.09	150.00	0.21	Calls on Galderma
25 Oct 25	BB Biotech	Q3 result	CHF 37.60	Call	SQPBTU	20 Mar 26	6.42	40.00	0.24	Calls on BB Biotech
27 Oct 25	SIG Combibloc	Q3 result	CHF 8.25	Call	SIOBBU	20 Mar 26	5.39	8.50	0.15	Calls on SIG Combibloc
27 Oct 25	Bucher Ind.	Q3 result	CHF 379.50	Call	BJUSOU	20 Mar 26	8.71	400.00	0.17	Calls on Bucher Ind.
27 Oct 25	Holcim	Q3 result	CHF 66.40	Call	SGEBHU	20 Mar 26	9.25	70.00	0.28	Calls on Holcim
				Put	SESBJU	20 Mar 26	7.36	65.00	0.37	Puts on Holcim
27 Oct 25	Ems	Q3 result	CHF 555.00	Call	SNAB5U	20 Mar 26	9.48	580.00	0.08	Calls on Ems
28 Oct 25	Novartis	Q3 result	CHF 104.62	Call	BFTSSU	20 Mar 26	13.25	110.00	0.20	Calls on Novartis
				Put	SSEBSU	20 Mar 26	9.07	100.00	0.30	Puts on Novartis
28 Oct 25	Temenos Group	Q3 result	CHF 65.00	Call	B0DS6U	20 Mar 26	5.01	66.00	0.28	Calls on Temenos Group

Source: Refinitiv, UBS.

As of: 13 Oct 25. All prices are indicative.

Company Heartbeats

International companies - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Type	Suitable Warrants					More Warrants
					SIX symbol	Expiry	Leverage	Strike	Ask price	
21 Oct 25	Netflix	Q3 result	USD 1,220.08	Call	BGPS4U	20 Mar 26	7.55	1,300.00	0.76	Calls on Netflix
22 Oct 25	Tesla	Q3 result	USD 413.49	Call	BJNSHU	20 Mar 26	4.33	430.00	1.05	Calls on Tesla
				Put	SQDB2U	20 Mar 26	3.98	400.00	0.79	Puts on Tesla
22 Oct 25	SAP	Q3 result	EUR 231.15	Call	SWTB3U	20 Mar 26	7.97	240.00	0.29	Calls on SAP
27 Oct 25	Paypal	Q3 result	USD 69.84	Call	BBTSSU	20 Mar 26	6.10	75.00	0.11	Calls on Paypal
29 Oct 25	Alphabet	Q3 result	USD 237.49	Call	SEYBOU	20 Mar 26	6.86	245.00	0.90	Calls on Alphabet
29 Oct 25	Meta Platforms	Q3 result	USD 705.30	Call	S2KBMU	20 Mar 26	6.41	740.00	0.55	Calls on Meta Platforms
29 Oct 25	Microsoft	Q1 result	USD 510.96	Call	BX9STU	20 Mar 26	8.94	530.00	0.56	Calls on Microsoft
29 Oct 25	Dt.Bank	Q3 result	EUR 30.33	Call	SG5B6U	20 Mar 26	6.85	32.00	0.51	Calls on Dt.Bank
29 Oct 25	Amazon	Q3 result	USD 216.37	Call	BY4SNU	20 Mar 26	7.03	225.00	0.32	Calls on Amazon
30 Oct 25	Apple	Annual report	USD 245.27	Call	SXMB5U	20 Mar 26	8.58	255.00	0.28	Calls on Apple
30 Oct 25	Volkswagen	Q3 result	EUR 89.62	Call	BTWS4U	20 Mar 26	7.89	95.00	0.10	Calls on Volkswagen
30 Oct 25	Lufthansa	Q3 result	EUR 7.38	Call	BM1S6U	20 Mar 26	7.57	8.00	0.08	Calls on Lufthansa

Source: Refinitiv, UBS.

As of: 13 Oct 25. All prices are indicative.

Disclaimer

This material has been prepared by UBS AG or one of its affiliates ("UBS"). This material is only intended for the distribution permitted under the applicable law. It has not been prepared for the needs of a specific recipient. It is only published for information purposes and does not constitute an offer or an invitation to purchase or sell securities or associated financial instruments ("Instruments"). UBS accepts no liability (either expressly or tacitly) for the completeness or reliability of the information contained in this document, except for the information on UBS AG and its affiliates. The information should not be regarded by the recipients as a substitute for their own judgment. All the opinions contained herein may change without prior notice and contradict the opinions of other business areas of UBS due to the application of different assumptions and criteria. UBS is not obliged to keep the information up to date. UBS, its executives, employees or clients may have or have had a participation in the Instruments and may conclude transactions with them at any time. UBS may maintain or have maintained a relationship with the entities specified in this information. Neither UBS nor its affiliates, executives or employees are liable for losses resulting from the use of this information.

Structured derivatives do not constitute participation in collective investment schemes. For this reason they do not require approval from the Swiss Financial Market Supervisory Authority (FINMA). As a result, investors are not entitled to the specific investor protection provided by the Swiss Collective Investment Schemes Act (CISA).

Structured products are complex and involve a high risk. The intrinsic value of the investment instruments depends not only on the performance of the underlying asset, but also on the issuer's creditworthiness (credit risk), which can change over the duration of the product. In relation to any securities, currencies, financial instruments or other assets underlying a transaction to which this material relates, the values may fall as well as rise and past performance is not an indication of future performance. Before entering into any transaction, you should consult your own legal, supervisory, tax, financial and accounting advisors as you consider necessary. You should also make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) at your own discretion and based on your consultation with advisors as you consider necessary. Unless expressly agreed otherwise in writing, UBS does not act as financial advisor or fiduciary in any transaction. The terms and conditions of an investment are subject solely to the detailed provisions, including risk considerations, contained in the relevant product documentation. The product documentation, i.e. the prospectus and the Key Information Document (KID), can be obtained from the website keyinvest.ch/en.ubs.com, by entering the relevant security / ISIN. Before you invest in a product, please read the current prospectus and the Key Information Document (KID) carefully and thoroughly. UBS makes no representations or warranties with regard to any information contained herein, which originates from independent sources. This publication may not be copied or reproduced without UBS's prior written permission.

Not for distribution in the United States or to US persons. © UBS 2025. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. UBS prohibits the forwarding of this information without the approval of UBS.

Contact

keyinvest@ubs.com

+41 44 239 76 76*

ubs.com/keyinvest

*Please note that calls to numbers marked with * may be recorded. When you call these numbers, we assume that you consent to this practice.